The coronavirus pandemic is accelerating momentum nationwide for life sciences real estate demand, according to a recent report from JLL's Healthcare and Life Sciences team.
The report, 2020 Life Sciences Real Estate Outlook, outlines the nation's top life sciences cluster hubs (Boston and San Francisco top the list) and pinpoints emerging markets for life sciences real estate.
Audrey Symes, Research Director, JLL Healthcare and Life Sciences, joined BD+C's David Barista on the August 6 episode of The Weekly to discuss the primary drivers of growth across the nation's life sciences cluster hubs. Watch the highlights here:
Here are highlights from JLL's 2020 Life Sciences Real Estate Outlook (text from JLL):
Rankings of the top U.S. life sciences cluster hubs were released today in the JLL 2020 U.S. Life Sciences Outlook, which also tracks the progress of up-and-coming life science markets that are fast becoming options of choice for life science companies and investors alike. Emerging hubs are looking to real estate to boost productivity as they anticipate growth of the worldwide prescription drug market, expected to surpass $1 trillion by 2022.
Boston, San Francisco, and San Diego retained their rankings as leaders among U.S. life sciences ecosystems and top contenders for venture capital investment, capturing 70% of all venture capital (VC) investment in 2019. Boston and San Francisco also lead the other clusters significantly with respect to development, with 2.7 million square feet (MSF) and 4.0 MSF respectively under construction.
Massive infusion of venture capital is also quick to promote life sciences employment growth. In 2019, 11 of 14 cluster markets set or approached record VC funding levels, a significant positive for the reinforcement of cluster market strength, resilience and security.
New York, Los Angeles, and Philadelphia increased their cluster scores since 2019, reaching new peaks in venture capital funding and life sciences employment. As speed to market accelerates for many pharmaceuticals, proximity to incubators at major research institutions has also supported developing clusters such as Raleigh-Durham, Houston, and Maryland, which have attracted recent interest from developers such as ARE, Longfellow and Hines.
Additionally, the race for development of COVID-19-related vaccines is already beginning to energize demand in pharma-heavy New Jersey, a trend that should spread to more markets as 2020 progresses.
“Each cluster has a different specialty and occupies its own point along the maturity spectrum, providing a diverse range of options for investors and occupiers alike,” said Roger Humphrey, Executive Managing Director, JLL Life Sciences. “But they do a share a major commonality. Each cluster features a highly-educated workforce and ties to the research community, which in turn attracts a steady stream of multi-sourced investment that creates a need for institutional real estate.”
Beyond COVID-19’s recent acceleration of innovation in the life sciences industry, life-enhancing pharmaceuticals and medical devices have been increasingly sought out by Millennials reaching the peak of their earning potential and seeking personalized experiences.
And, the upcoming expiration of a suite of patents creates an opportunity for mid-tier life sciences companies to pursue new long-term profit sources. Many new products on the market and in development are curative rather than therapeutic, increasing marketing potential and overall category growth.
“Conditions are ideal for maximum profitability arising from innovative new pharmaceuticals and medical devices,” said Audrey Symes, Research Director, JLL Healthcare and Life Sciences. “Meaningful advances within the life sciences industry, such as machine learning, are creating new sources of workflow and thus real estate demand. This combination of simulative factors sets up the life sciences industry to expand at an unprecedented pace, both in terms of manufacturing and patient demand.”
Related Stories
Giants 400 | Nov 28, 2023
Top 100 Laboratory Design Firms for 2023
HDR, Flad Architects, DGA, Elkus Manfredi Architects, and Gensler top BD+C's ranking of the nation's largest laboratory architecture and architecture/engineering (AE) firms for 2023, as reported in Building Design+Construction's 2023 Giants 400 Report.
Giants 400 | Nov 16, 2023
Top 80 Science + Technology Facility Construction Firms for 2023
DPR Construction, Austin Industries, Whiting-Turner, and Gilbane top BD+C's ranking of the nation's largest science and technology (S+T) facility general contractors and construction management (CM) firms for 2023, as reported in Building Design+Construction's 2023 Giants 400 Report. Note: This ranking factors revenue from all science and technology (S+T) buildings work, including laboratories, research buildings, technology/innovation buildings, pharmaceutical production facilities, and semiconductor production facilities.
Giants 400 | Nov 16, 2023
Top 70 Science + Technology Facility Engineering Firms for 2023
Jacobs, Fluor, SSOE, Tetra Tech, and Affiliated Engineers head BD+C's ranking of the nation's largest science and technology (S+T) facility engineering and engineering/architecture (EA) firms for 2023, as reported in Building Design+Construction's 2023 Giants 400 Report. Note: This ranking factors revenue from all science and technology (S+T) buildings work, including laboratories, research buildings, technology/innovation buildings, pharmaceutical production facilities, and semiconductor production facilities.
Giants 400 | Nov 16, 2023
Top 100 Science + Technology Facility Architecture Firms for 2023
Gensler, HDR, Page Southerland Page, Flad Architects, and DGA top BD+C's ranking of the nation's largest science and technology (S+T) facility architecture and architecture/engineering (AE) firms for 2023, as reported in Building Design+Construction's 2023 Giants 400 Report. Note: This ranking factors revenue from all science and technology (S+T) buildings work, including laboratories, research buildings, technology/innovation buildings, pharmaceutical production facilities, and semiconductor production facilities.
Laboratories | Nov 8, 2023
Boston’s FORUM building to support cutting-edge life sciences research and development
Global real estate companies Lendlease and Ivanhoé Cambridge recently announced the topping-out of FORUM, a nine-story, 350,000-sf life science building in Boston. Located in Boston Landing, a 15-acre mixed-use community, the $545 million project will achieve operational net zero carbon upon completion in 2024.
Laboratories | Sep 20, 2023
Life sciences construction market is poised for a comeback: JLL
The life sciences commercial real estate market has undergone a reset this year but is well positioned to be the comeback kid as capital sources grow more confident and green shoots emerge, according to JLL’s 2023 Life Sciences Industry and Real Estate Perspective.
Laboratories | Aug 24, 2023
Net-zero carbon science center breaks ground in Canada
Designed by Diamond Schmitt, the new Atlantic Science Enterprise Centre (ASEC) will provide federal scientists and partners with state-of-the-art space and equipment to collaborate on research opportunities.
Giants 400 | Aug 22, 2023
Top 115 Architecture Engineering Firms for 2023
Stantec, HDR, Page, HOK, and Arcadis North America top the rankings of the nation's largest architecture engineering (AE) firms for nonresidential building and multifamily housing work, as reported in Building Design+Construction's 2023 Giants 400 Report.
Giants 400 | Aug 22, 2023
2023 Giants 400 Report: Ranking the nation's largest architecture, engineering, and construction firms
A record 552 AEC firms submitted data for BD+C's 2023 Giants 400 Report. The final report includes 137 rankings across 25 building sectors and specialty categories.
Giants 400 | Aug 22, 2023
Top 175 Architecture Firms for 2023
Gensler, HKS, Perkins&Will, Corgan, and Perkins Eastman top the rankings of the nation's largest architecture firms for nonresidential building and multifamily housing work, as reported in Building Design+Construction's 2023 Giants 400 Report.